+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis



Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis



Expert Review of Proteomics 14(9): 769-777



Amyotrophic lateral sclerosis (ALS) is a progressive degenerative motor neuron disease, which usually leads to death within a few years. The diagnosis is mainly based on clinical symptoms and there is a need for ALS-specific biomarkers to make an early and precise diagnosis, for development of disease-modifying drugs and to gain new insights into pathophysiology. Areas covered: In the present review, we summarize studies using mass spectrometric (MS) approaches to identify protein alterations in the cerebrospinal fluid (CSF) of ALS patients. In total, we identified 11 studies fulfilling our criteria by searching in the PubMed database using the keywords 'ALS' and 'CSF' combined with 'proteome', 'proteomic', 'mass spectrometry' or 'protein biomarker'. Ten proteins were differently regulated in ALS CSF compared to controls in at least 2 studies. We will discuss the relevance of the identified proteins regarding the frequency of identification, extent of alteration and brain-specificity. Expert commentary: Most of the identified CSF biomarker candidates are irreproducible or mainly blood-derived. We assign the missing success of CSF proteomic studies in biomarker discovery to a lack of sensitivity, unsuitable normalization, low quality assurance and variations originating from sample preparation. These issues must be improved in future proteomic studies in CSF.

(PDF emailed within 0-6 h: $19.90)

Accession: 060148192

Download citation: RISBibTeXText

PMID: 28799854

DOI: 10.1080/14789450.2017.1365602


Related references

Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. Journal of Neurochemistry 95(5): 1461-1471, 2005

Proteomic profiling of cerebrospinal fluid to identify diagnostic biomarkers for amyotrophic lateral sclerosis. FASEB Journal 18(4-5): Abst 151 5, 2004

Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis. Journal of Proteome Research 14(11): 4486-4501, 2016

Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis. Experimental and Therapeutic Medicine 11(6): 2095-2106, 2016

Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Annals of Neurology 83(2): 258-268, 2018

Cerebrospinal Fluid Biomarkers for Kii Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex. Journal of Neurodegenerative Diseases 2013: 679089, 2013

Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients. Neuromolecular Medicine 18(4): 551-560, 2016

Proteomic analysis of the cerebrospinal fluid from patients with amyotrophic lateral sclerosis based on tandem mass spectrometry technique. Nan Fang Yi Ke Da Xue Xue Bao 39(4): 428-436, 2019

Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid. Bmc Medical Genomics 12(1): 7-7, 2019

Cerebrospinal fluid biomarkers for Alzheimer's disease in patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis with the C9ORF72 repeat expansion. Dementia and Geriatric Cognitive Disorders 39(5-6): 287-293, 2015

Immunological studies of the cerebrospinal fluid in patients with amyotrophic lateral sclerosis. Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 91(2): 29, 1991

Is cerebrospinal fluid obtained for diagnostic purpose a good material for biomarker studies in amyotrophic lateral sclerosis?. Biomarkers 19(7): 571-577, 2015

Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle and Nerve 42(1): 104-111, 2010

Cerebrospinal fluid filtration in amyotrophic lateral sclerosis. European Journal of Neurology 6(5): 597-600, Sept, 1999

Cerebrospinal fluid proteins in the course of amyotrophic lateral sclerosis. Revue Neurologique 125(5): 393-400, 1971